Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation and Depletion (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Depreciation and Depletion data on record, last reported at $8.1 million in Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 11.22% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $31.6 million, up 12.03%, while the annual FY2025 figure was $31.6 million, 12.03% up from the prior year.
  • Depreciation and Depletion reached $8.1 million in Q4 2025 per AMPH's latest filing, up from $7.9 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $8.3 million in Q2 2025 and bottomed at $5.4 million in Q3 2021.
  • Average Depreciation and Depletion over 5 years is $6.6 million, with a median of $6.3 million recorded in 2023.
  • The widest YoY moves for Depreciation and Depletion: up 20.57% in 2021, down 2.84% in 2021.
  • A 5-year view of Depreciation and Depletion shows it stood at $5.4 million in 2021, then grew by 14.9% to $6.2 million in 2022, then grew by 7.19% to $6.6 million in 2023, then grew by 9.19% to $7.3 million in 2024, then grew by 11.22% to $8.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation and Depletion were $8.1 million in Q4 2025, $7.9 million in Q3 2025, and $8.3 million in Q2 2025.